Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Cancers · 19.11.2026 · 18 (22) · 3702
DOI: 10.3390/cancers18223702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Haticegul Tuncer und 5 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe, Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Venous thromboembolism is common during neoadjuvant chemotherapy for advanced ovarian cancer, but when to start thromboprophylaxis is unclear. We evaluated the association between early prophylactic-dose low-molecular-weight heparin, started at diagnosis or before the first cycle, and venous thromboembolism during neoadjuvant chemotherapy.
Methods
This retrospective single-center cohort study included all consecutive women with stage III–IV epithelial ovarian cancer diagnosed between September 2012 and January 2025 who received neoadjuvant chemotherapy. Patients with venous thromboembolism at diagnosis were excluded. The primary endpoint was confirmed venous thromboembolism from the first cycle until interval debulking surgery or, without surgery, until completion of planned neoadjuvant chemotherapy or day 120, whichever occurred first. Associations were explored with Firth-penalized logistic regression.
Results
Of 201 patients who received neoadjuvant chemotherapy, 192 formed the analytic cohort; 148 (77.1%) received early prophylaxis. Primary endpoint events occurred in 7 patients (3.6%; six pulmonary embolisms) at a median of 3.1 weeks after diagnosis. Events occurred in 1 of 148 patients (0.7%) with early prophylaxis and 6 of 44 (13.6%) without it. In exploratory multivariable analysis, early prophylaxis remained associated with lower odds (adjusted odds ratio [OR] 0.08, 95% confidence interval [CI] 0.01–0.47). A Khorana score of 3 or higher was associated with higher, imprecisely estimated odds (adjusted OR 12.70, 95% CI 1.17–1722). No major or clinically relevant non-major bleeding was identified (0/148 with prophylaxis; 95% CI 0–2.46%).
Conclusions
Early prophylactic-dose low-molecular-weight heparin was associated with fewer venous thromboembolic events during neoadjuvant chemotherapy. Because prophylaxis was not randomized and events were few, these hypothesis-generating findings require prospective validation.
Zitieren
APA
Tuncer, H., Ergisi, S., Ege, H. V., Gultekin, M., Tuncer, Z. S., & Basaran, D. (2026). Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Cancers, 18(22), 3702. https://doi.org/10.3390/cancers18223702
Vancouver
Tuncer H, Ergisi S, Ege HV, Gultekin M, Tuncer ZS, Basaran D. Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Cancers. 2026;18(22):3702. doi:10.3390/cancers18223702
BibTeX
@article{Tuncer2026,
author = {Tuncer, Haticegul and Ergisi, Semih and Ege, Hasan Volkan and Gultekin, Murat and Tuncer, Zafer Selcuk and Basaran, Derman},
title = {Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3702},
doi = {10.3390/cancers18223702}
}
EUVIMED